Hyperfine (HYPR) Expected to Announce Earnings on Wednesday

Key Points

• Hyperfine (NASDAQ:HYPR) is set to announce its Q2 2025 earnings on August 13th, with analysts expecting a loss of ($0.12) per share and revenue of $3.00 million.
• The company reported a negative return on equity of 74.19% and a net margin of 343.42% in its last earnings report, with revenue of $2.14 million.
• Analysts' opinions on the stock are mixed; Wells Fargo lowered its target price from $1.29 to $0.68, while B. Riley maintained a "buy" rating.

Hyperfine (NASDAQ:HYPR - Get Free Report) is anticipated to announce its Q2 2025 earnings results after the market closes on Wednesday, August 13th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $3.00 million for the quarter. Hyperfine has set its FY 2025 guidance at EPS.

Hyperfine (NASDAQ:HYPR - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.12) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.12). Hyperfine had a negative net margin of 343.42% and a negative return on equity of 74.19%. The firm had revenue of $2.14 million for the quarter, compared to analyst estimates of $2.82 million. On average, analysts expect Hyperfine to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Hyperfine Trading Up 0.9%

HYPR traded up $0.01 during trading on Friday, reaching $1.16. 158,876 shares of the company's stock were exchanged, compared to its average volume of 520,997. Hyperfine has a one year low of $0.53 and a one year high of $1.90. The stock has a market capitalization of $90.28 million, a PE ratio of -2.15 and a beta of 1.06. The firm has a fifty day moving average price of $0.87 and a two-hundred day moving average price of $0.86.

Analyst Ratings Changes

HYPR has been the topic of a number of research reports. Wells Fargo & Company reduced their target price on shares of Hyperfine from $1.29 to $0.68 and set an "equal weight" rating on the stock in a report on Wednesday, May 14th. B. Riley reaffirmed a "buy" rating on shares of Hyperfine in a research note on Tuesday, June 3rd.

Hyperfine Company Profile

Hyperfine, Inc, a medical device company, provides magnetic resonance imaging (MRI) products in the United States. The company offers Swoop Portable MR imaging system, which offers portable brain neuroimaging; and support and technical assistance services. It serves ICU, comprehensive, and primary stroke accredited facilities through direct sales and distributors.